Blüm Study – Phase 3 clinical trial for autistic kids

Views: 7

RYE, N.Y.— Curemark, LLC announced on Friday that the Blüm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at 30 clinical sites across the United States.

“There are limited medical treatment options available for children with Autism, particularly for children aged 3-8, which is when Autism is generally diagnosed,” said Dr. Joan Fallon, CEO of Curemark. “CM-AT has the potential to serve this clear unmet medical need. With all 30 of our clinical trial sites now enrolling across the United States, we look forward to the trial’s completion and submitting our New Drug Application for CM-AT.”

This 14-week, double-blind, randomized, placebo-controlled Phase 3 study is designed to determine if CM-AT may help improve core and non-core symptoms of Autism. CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. – PRNewswire

Comments: 0

Your email address will not be published. Required fields are marked with *